Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Machelle Manuel, PhD, discusses further gout treatment options to consider when target serum urate levels are not attained.
Machelle Manuel, PhD, is vice president, Medical Scientific Affairs, at Ironwood Pharmaceuticals, the manufacturer of lesinurad.
Please login or register first to view this content.
Enjoying our content?
Thanks for visiting Rheumatology Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Rheumatology Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Please login or register first to view this content.